GlassScriptPhysician profile
David G Vermillion
NPI 1093718801
$4,985.92
in general payments reported to CMS, 2019-2025
36 companies · $48.54 in 2025
The $48.54 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,674 · 2020: $182 · 2021: $655 · 2022: $1,096 · 2023: $527 · 2024: $803 · 2025: $48.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,330 · Education: $48.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,330.06 |
| Education | $48.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $737.32 | 2019-2024 | Jardiance, Tradjenta |
| Janssen Pharmaceuticals, INC | $717.24 | 2019-2024 | Spravato, Xarelto |
| Novo Nordisk INC | $563.95 | 2019-2025 | Ozempic, Wegovy |
| Amgen INC. | $465.01 | 2019-2024 | Evenity, Prolia |
| Glaxosmithkline, LLC. | $331.19 | 2019-2023 | Trelegy Ellipta |
| Pfizer INC. | $300.88 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $160.75 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $153.78 | 2020-2024 | Mounjaro, Jardiance |
| Allergan, INC. | $152.14 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $150.64 | 2019-2024 | Eliquis |
| Electromed, INC. | $144.19 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $129.22 | 2022-2023 | |
| Abbvie INC. | $107.13 | 2022-2024 | Qulipta, Ubrelvy |
| Teva Pharmaceuticals USA, INC. | $88.31 | 2019-2020 | |
| Edwards Lifesciences Corporation | $79.43 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $70.44 | 2019-2024 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.51 | 2022-2023 | Xifaxan |
| Sunovion Pharmaceuticals INC. | $62.34 | 2019 | |
| Novartis Pharmaceuticals Corporation | $62.33 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $49.33 | 2021-2023 | Qelbree |
| Esperion Therapeutics, INC. | $44.13 | 2020-2021 | |
| Eisai INC. | $42.90 | 2024 | |
| Sanofi-Aventis U.S. LLC | $42.88 | 2019-2022 | |
| Exact Sciences Corporation | $33.91 | 2023-2024 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $32.97 | 2019 | |
| Philips North America LLC | $28.59 | 2019 | |
| Sobi, INC | $27.08 | 2019 | |
| Axsome Therapeutics, INC. | $26.04 | 2022 | |
| Portola Pharmaceuticals, LLC | $19.20 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $18.43 | 2021 | |
| Cranial Technologies, INC | $14.84 | 2021 | |
| Advanced Respiratory, INC | $14.29 | 2019 | |
| Orexo US, INC. | $14.13 | 2022 | |
| Evofem Biosciences, INC. | $13.42 | 2021 | |
| Inspire Medical Systems, INC. | $13.23 | 2024 | Inspire |
| Sanofi Pasteur INC. | $11.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Vermillion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.